🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

RecruitingPhase 2Ages 18 Years - 75 YearsAllXinqiao Hospital of Chongqing
NCT06947694 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. The main objective is to find the optimal organ combination and the best radioimmunotherapy combination pattern.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient must meet all of the following inclusion criteria to be enrolled in this study: 1. Non-small cell lung cancer diagnosed initially through pathological histology. 2. There are 3-6 metastatic lesions. 3. No brain metastasis or the lesions are stable. 4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET genes. Note: The above English terms are all gene names). 5. ECOG (Eastern Cooperative Oncology Group) score: 0-1 point, with an expected, survival period of more than 3 months. 6. Aged between 18 and 75 years old. 7. Evaluated by PET-CT (including FDG and FMISO, not mandatory). 8. No contraindications for immunotherapy and radiotherapy. 9. The informed consent form has been signed. Exclusion Criteria: * Patients with any of the following criteria are not eligible for enrollment in this study: 1. Those with severe dysfunction of vital organs (heart, liver, kidney). 2. Those accompanied by other malignant tumors. 3. Those with uncontrolled heart diseases or having experienced a myocardial infarction within the past six months. 4. Those with a history of mental illness. 5. And other situations in which the researchers deem it inappropriate for the subjects to participate in the study.
💊

What it tests

  • chemotherapy + PD-1 inhibitors
  • chemotherapy + PD-1 inhibitors
  • chemotherapy + PD-1 inhibitors
  • chemotherapy + PD-1 inhibitors
  • chemotherapy + PD-1 inhibitors
📍

Where

1 site
the second affiliated hospital of Army medical university
Chongqing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy